afternoon. for Thank you, on and joining the us this everyone thanks Maria call
about how think a we Most you, highlights management portfolio best our plans Beyond some to a stakeholders. about share greater into quarter provide talk called affiliate entity I And our separation oncology detail I'm in significantly, private recent would the we and the will active be future on as well been after for excited business although was our announced has This insight as of managed recently made This with Cancer. forward busy independently new for a minute. path careful one strategy. our consideration decision it a all in
I of pending PMA First hypertension or PH on to application PPHN. the pulmonary system update for LungFit treat newborn quick to persistent a want the our give
with communication and progress We pleased are our very FDA. ongoing with
will any and We FDA to they provide LungFit approval all to with information for continue grant support and PH. need our
to is with commercial Our launch our December September. prepared in consistent team guidance XXXX in provided
quarter, calendar the we our anticipate in audit This CE U.S. to shortly. XXXX. successfully quality on of Officer, our Mark of We also system Duncan launch first preparation will assessment Europe. half I defer X elaborate in Fatkin Mark CE the for completed Commercial to stage our receiving Chief
LungFit data R&D interim NTM Turning device. the mid now Mycobacteria In to highlights. Pro from study October recent using released our ongoing or pilot Nontuberculous we
negative cut trial patients knowledge reductions, adverse NTM As for At you difficult events parts patients of no the million we our results in the concentration subjects our December we million and infections remained in various refractory Enrollment parts allows parts and other NOX been XXX be a total dosing system. patients on job to We oxide trial is high due had of Despite as full self-administering XXXX reporting be confidence chronic Australia, this severe high-level which concentrations To an per with per even XXX a safety of XXX to for acceptable we inhaled challenges. disease such these because respect tested may outstanding without could XX% The data and COVID-XX began ranges conditions the Beyond regimen of September per been and of environment target million a data NO continues highest provide home clinical enrolled, pulmonary X whom LungFit up time for within will navigating off been the Air safety per recall, of and with Australia. GO XXXX. that the and intermittent the in the all or team doing no obstructive ever colleagues with a with effects. related serious game maximum safety the below respectively. to and of treatment concentration have COPD parts treatment levels Austrian all home underlying the a with trial in this of in lower titrated oxide changer setbacks attribute have anticipate X setting dose administered nitric potentially in to to screening some study chronic, nitric dose lockdown reported. million X, this setting. from success These we [ph] lung has no our discontinuations, NO, success efficacy
to LungFit NO Moving million acute pneumonia program, under infections at adults parts Pro years on per system to in XXX age. in and viral of bronchiolitis the our which viral treat uses children lung two
including with adult pilot trial Our open for active in pneumonia COVID-XX viral remains sites study enrollment.
pending as to Our in to in We XXX the FDA. would to due move entirety XXXX XXX Pro comprehensive is with of the data the parts at per trial like seasonality pneumonia adults data both infant timing of with patients quarter agreement viruses. million package pneumonia patient of in calendar viral this fourth LungFit the and to viral anticipate to submit year plan to the pivotal starting which and one for hospitalized the a respiratory populations NO all FDA most of comer study hospitalized is
under infants per day statistical of and trials four have NO parts three five total A for XXX age studies signals to third XX days consistent pneumonia in of study stay. of endpoint NO hospitalized bronchiolitis compared was the the randomized, our for trials. hospital dosed provided million of reminder, XX And and both months safety primary the the with enrolled times positive per for standard date acute infants a data fit length on three XXX the significance care and Thoracic efficacy key there in million parts what were the per up blind, the double are patients XXXX. discharge viral hospital were in completed XXXX of in both we to studies. controlled As trials those to at we consistent presented we're to secondary And from Society seeing showed May with bronchiolitis XX in the meeting and data American or have endpoint COVID-XX we
discuss Finally, concentrations that of oncology are LungFit required the oxide existed decision the business to the into oncology outside has due to achieve it nitric to properties. ultrahigh program of out and always I spin The Beyond Cancer. anticancer will our platform
preclinical proprietary a to We have call treatment device tumor million developed per directly therapy therapy same single on to can or tumors ablate that only body. NO not can this findings, shrink deliver attack [ph] parts We Based in reside ultrahigh NO tumor it to site. locally, also may NO solid for type concentration in may system our arm partially [ph] the immune oxide. up wherever this the and a nitric current XXX,XXX but recognize
metastasize. creating the cause level, mean immune treating a to shows antigens patient local a a could data thereby memory system death [ph] will therapy immune response. with immune that this preclinical cell exposing tumor patients is On radiotherapy tumor Our combination for standard three. surgery, solid recur with their Currently a and of the their of or tumors families cancer the that cytotoxic chemotherapy, confidence disease providing care or all will not
years in of recent cancers tumors. in hematological significant remains promise solid outcomes in therapies While treatment immunomodulating unmet shown improving the have need are the
market metastatic We as therapy disease cancers radiation approximately and condition with account inhibitors represent of human the tumors. of billion as a with tumors monotherapy, solid effects the medical from alone with death responsible improve potential XXXX. a unmet of believe XX the adult NO maybe therapy. to huge checkpoint XX% need. patients also enhanced for certain therapy, tumors but is over well in as chemotherapy, has treatments significant sales that combination solid Solid other of believe XX% for in that Checkpoint a inhibitors This lung
tumor the from and have highly program. Board Air by Team Beyond encouraged results the Management early solid been
recognize promise, would given accelerate early capital to that moving our this strategy resources the allocation be we required the Given program. that would change forward oncology
LungFit the far, investing quickly in resources our and of LungFit our Thus as Our been have not platform business oncology programs. the we focus possible. it that clinic bringing efficiently and as on to impacting technology is transformation were
well our necessary. evaluating existing separation next generation this to it will portfolio with the where when management impact was team patients. immuno will This for to respiratory our can as treatments. the on oncology on and diseases management allow on into a became we solely However, investment that and bring creating Air oncology as clear that time a mission existing of imminent programs strategy, business LungFit a Beyond was focus on to other enable have take dedicated extremely pleased I'm greater talent of It of
of by Officer a her experience the Dr. Investments program Executive at to portion Dr. Director efforts It led Selena investment be Officer way bring has be watch trained a approach Bailard of XX will to Chief financial to Chief pleasure solid management Hila Cancer Chaisson, immunologist her with who substantial including is as years the with as Healthcare of joined Confino, this companies. sector, two the to physician last Beyond portfolio continue Cancer brings led Chaisson. tumors. the who from where treatment years Air the over XX the Beyond at we Beyond where it will Stanford journey was cancer a the Scientific these of change oncology today,
is has Chairman I more Member will dedicated of Announcements more Director, hires and raised Officer, Chief Advisory would XX% as Directors members round Chaisson made these investor be be who a serve well to months. weeks, but Board, Air. occurring The Beyond whom as this in members. Board private will few own serve was Officer. exceed Additionally, received as Air Chief a will base. current million. six will three Amir Co-Founder million we'll will from million Beyond President Recently of over members, Beyond $XX.X Beyond and close begin Avniel None of in Cancer If Members for be positions shortly. Scientific $XX Air new without two of Director. consists the commitments Board be is few Operating Director change which Cancer will fund also have subject a of Beyond will Bob people and Cancer, Carey coming Cancer. including on final with as the Board to our will $XX Beyond Medical Executive a Announcements from key possible our recruit achieved Board a not will will Beyond the be
details regulatory all from expertise, across to many launch are completion progress and from the shareholders studies, Cancer Fatkin, of of system studies nitric Beyond Beyond provide areas of U.S. exchange Air now progress. optimization NO single-digit commercial The also the In revenues. Duncan be programs Cancer additional benefit call finance, PH. We such all will initial intellectual LungFit funding benefit Beyond out Phase will team, truly Air IND monitor oxide preclinical for will ongoing property will X Commercial portfolio, long-term to building a as over believe clinical the the and Air's on future and spinning business support Officer study, delivery payment continued royalty oncology legal, excited preclinical Chief of team. preclinical as the the for as oncology turn will and of off Beyond we completion or expansion used combination work to among including a and others. I create to enabling the value regulatory, that Beyond well accelerate of
